ORIC Pharmaceuticals is a privately-held cancer therapy company focused on the discovery and development of small-molecule drugs that target treatment-resistant cancers, beginning with advanced prostate cancer. ORIC is leveraging its deep clinical understanding of the molecular mechanisms of cancer-treatment resistance, with its robust discovery platform, to develop new lines of therapies that will overcome resistance in cancer. The company brings together distinguished scientific founders, a leadership team and Board comprised of seasoned drug developers with proven track records, to solve the pervasive problem of resistance to cancer treatment. The company launched in 2014 and is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/02/15 | $53,000,000 | Series B |
EcoR1 Capital Foresite Capital Kravis Investment Partners OrbiMed Advisors The Column Group Topspin Partners | undisclosed |
